Compare RLI & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLI | APGE |
|---|---|---|
| Founded | 1965 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | RLI | APGE |
|---|---|---|
| Price | $58.08 | $73.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $66.00 | ★ $101.20 |
| AVG Volume (30 Days) | 620.1K | ★ 706.6K |
| Earning Date | 04-22-2026 | 03-02-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | ★ 16.84 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $1,882,448,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $55.80 | $26.20 |
| 52 Week High | $81.79 | $84.56 |
| Indicator | RLI | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 52.88 |
| Support Level | $55.80 | $73.06 |
| Resistance Level | $63.45 | $79.29 |
| Average True Range (ATR) | 1.43 | 4.17 |
| MACD | -0.46 | 0.19 |
| Stochastic Oscillator | 8.04 | 49.52 |
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety, and it derives a majority of its revenue from the Casualty segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.